Sanaa A. El-Gizawy

Sanaa A. El-Gizawy

Auto-generated profile, based on publicly available information

Sanaa A. El-Gizawy

Department of Pharmaceutical Technology, Faculty of Pharmacy, Tanta University, Tanta, Egypt

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2007 in AAPS PharmSciTech
Verified
Journal Article
Closed access
PDF file
IAIsmail A. Attia
Ismail A. Attia
SESanaa A. El-Gizawy
Sanaa A. El-Gizawy
MFMedhat A. Fouda
Medhat A. Fouda
ADAhmed M. Donia
Ahmed M. Donia

1 January 2015 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
SESanaa A. El-Gizawy
Sanaa A. El-Gizawy
MOMohamed A. Osman
Mohamed A. Osman
MAMona F. Arafa
Mona F. Arafa
GMGamal M. El Maghraby
Gamal M. El Maghraby

1 January 2017 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
ASAmal A. Sultan
Amal A. Sultan
SESanaa A. El-Gizawy
Sanaa A. El-Gizawy
MOMohamed A. Osman
Mohamed A. Osman
GMGamal M. El Maghraby
Gamal M. El Maghraby

23 June 2023 in AAPS PharmSciTech
Verified
Journal Article
Open access
PDF file
Mohamed NasrMohamed Nasr
Mohamed Nasr
Ahmed Youssef KiraAhmed Youssef Kira
Ahmed Youssef Kira
Sameh SaberSameh Saber
Sameh Saber
EEEbtessam Essa
Ebtessam Essa
SESanaa A. El-Gizawy
Sanaa A. El-Gizawy
Hepatocellular carcinoma (HCC) has a significant economic impact and a high mortality rate. Telmisartan (TLM) is a potential therapy for HCC, but it has a limited scope in drug delivery due to unpredictable distribution and poor bioavailability. The objective of this study was to prepare, design, and in vitro evaluate lactose-modified chitosan nanoparticles (LCH NPs) as a liver-targeted nanocarrier for TLM with the potential to offer a promising HCC therapy. The combination of chitosan with lactose was successfully attained using the Maillard reaction. TLM-LCH NPs were prepared, characterized, and optimized with the developed 23 full factorial design. The optimized formulation (F1) was in vitro and in vivo characterized. LCH was synthesized with an acceptable yield of 43.8 ± 0.56%, a lactosylation degree of 14.34%, and a significantly higher aqueous solubility (6.28 ± 0.21 g/L) compared to native chitosan (0.25 ± 0.03 g/L). In vitro characterization demonstrated that, F1 had a particle size of 145.46 ± 0.7 nm, an entrapment efficiency of 90.21 ± 0.28%, and a surface charge of + 27.13 ± 0.21 mV. In vitro TLM release from F1 was most consistent with the Higuchi model and demonstrated significantly higher release at pH 5.5. Moreover, a significantly higher ratio of liver to plasma concentration was observed with TLM-LCH NPs compared to plain TLM and unmodified TLM-NPs. The obtained results nominate TLM-LCH NPs as a promising carrier for enhancing liver targeting of TLM in treatment of HCC. Graphical abstract

1 August 2017 in International Journal of Pharmacy and Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
SGSanaa El Gizaway
Sanaa El Gizaway
MFMaha Fadel
Maha Fadel
BMBasma Mourad
Basma Mourad
FEFatma El-Zahraa Abd Elnaby
Fatma El-Zahraa Abd Elnaby
Objective: The main aim of this study was to design and characterise betamethasone di-propionate loaded transfersomes (BD-T); as a topical formulation for the treatment of localized plaque psoriasis.Methods: A full factorial design (23) was applied to study the effects of three independent variables: drug content, type of surfactants and surfactant contents on particle size (PS), entrapment efficiency (EE %), zeta potential (ZP), polydispersity index (PI) and drug release profiles. The optimized BD-T was formulated as a hydrogel using 5% sodium carboxymethyl cellulose. The gel was characterized for viscosity, drug content, in vitro drug release and stability. A comparative clinical study was performed on 20 patients with psoriasis to investigate the effect of BD-T gel and the marketed betamethasone dipropionate (BD) cream.Results: The optimized BD-T formulation containing 50 mg betamethasone dipropionate (BD) and 5 mg tween 80 showed spherical unilamellar vesicles with an average particle size of 242.80, % EE of 90.19%, ZP of-15.00 mV, PI of 0.407 and K0 of 4.290 mg/hr. The formulation showed good stability at 4 °C and 25 °C for 6 mo. The results revealed significant clinical improvement and a significant increase in safety and tolerability with BD-T gel compared with BD cream.Conclusion: As a conclusion, BD-T was found to be more effective, safe and tolerable for the treatment of psoriasis compared with the marketed product.

10 March 1999 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
SESanaa A. El-Gizawy
Sanaa A. El-Gizawy
MHMohsen A. Hedaya
Mohsen A. Hedaya